USA Mitchell Cancer Institute

Recent papers from USA Mitchell Cancer Institute

1. Extramedullary Disease and Prolonged Hematotoxicity After Standard-of-Care Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: A Transatlantic Real-World Evidence SynthesisCurrent Oncology · 2026
2. Sequencing BCMA-Directed Therapies in Relapsed/Refractory Multiple Myeloma: A Real-World Comparison of CAR T-Cell Therapy and Bispecific AntibodiesCancers · 2026
3. Barriers encountered and implementation strategies deployed to facilitate real-world remote symptom monitoring in patients receiving active cancer treatmentFrontiers in Health Services · 2026
4. DNA FragmentLength Analysis Using Machine LearningAssisted Vibrational SpectroscopyACS Measurement Science Au · 2026
5. Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trialThe Lancet · 2026
6. Efficacy of high‐frequency low‐dose rituximab and acalabrutinib in chronic lymphocytic leukemiaHemaSphere · 2026
7. Palliative Care Coaching for Family Caregivers of Patients With Advanced CancerJAMA Network Open · 2026
8. Evaluation of Real-World Studies on Management of Relapsed Multiple Myeloma After BCMA-Directed Therapy Failure from U.S. Academic Centers and USMIRCCurrent Oncology · 2026
9. Mezigdomide, carfilzomib, and dexamethasone (MeziKd) vs carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): Results from the phase 3 SUCCESSOR-2 trial.Journal of Clinical Oncology · 2026
10. Prognostic Significance of KRAS G12C Versus Non-G12C RAS Mutations in Metastatic Colorectal Cancer: A Systematic Review and Meta-AnalysisThe Oncologist · 2026
11. Patterns and timing of palliative care consultation in patients with newly diagnosed metastatic cancer.Journal of Clinical Oncology · 2026
12. Nicotinamide riboside and pterostilbene reduces frequency and severity of undesirable symptoms of the menopause transition: an open-label, pilot clinical trialFrontiers in Aging · 2026
13. IL1β/IL1R1/IRAK4 Drives Inflammatory Ovarian Cancer Seeding at the inflamed sites and Is Reversed by an IRAK4 inhibitor UR241-22026
14. Genome-Wide DNA Methylation Profiling Reveals Ancestry-Associated Epigenetic Reprogramming in Cervical Intraepithelial NeoplasiaInternational Journal of Molecular Sciences · 2026
15. Angiotensin II type 1 receptor blockade inhibits gastric cancer metastasis through tight junction restorationCancer Letters · 2026
16. High-Risk Cytogenetic Multiple Myeloma Remains a Therapeutic Challenge: A 15-Year Real-World AnalysisCurrent Oncology · 2026
17. A meta‐analysis of perceived infectability, germ aversion, disgust and outgroup perceptions: Evaluating research on the behavioural immune systemBritish Journal of Psychology · 2026
18. Abstract SY23-01: Lineage tracing of the intercellular transfer of mitochondria during cancer progressionCancer Research · 2026
19. Ubiquitylation of DNA polymerase β via atypical K27 chains signals a DNA damage responseNucleic Acids Research · 2026
20. Complement-mediated ADCP as a distinct and finite cytotoxic mechanism of monoclonal antibodiesFrontiers in Immunology · 2026